RGDO News Alert Regado Biosciences Inc (RGDO) 0.89 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regado Biosciences Inc (RGDO) 0.89 $RGDO

5 Stock Losers of 2014 That Could Soar Next Year - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Dec 23, 9:25AM CST
The year was not without its headwinds.
ANV: 0.88 (+0.02), NEON: 2.68 (+0.10), MTL: 0.71 (-0.06), TCS: 20.22 (+0.20), RGDO: 0.89 (unch)

Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.35 (+0.21), ISIS: 59.49 (+1.88), GLYC: 7.81 (-0.42), RGDO: 0.89 (unch)

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/l6bhq9/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Bayer AG - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/l6bhq9/deep_vein
BMY: 59.15 (-0.01), RGDO: 0.89 (unch)

Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST

LOXO: 13.50 (+0.06), TRGT: 2.73 (+0.08), BOTA: 2.26 (unch), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BIOS: 6.37 (unch), RGDO: 0.89 (unch), EXEL: 1.29 (-0.01), AMPH: 11.74 (-0.09)

Regado Biosciences' (RGDO) CEO Michael Metzger on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 9:17AM CST

RGDO: 0.89 (unch)

Regado Biosciences beats by $1.04
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:14PM CST

RGDO: 0.89 (unch)

Regado Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
PR Newswire - Wed Nov 05, 3:30PM CST
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced its third quarter 2014 financial results. A conference call and webcast to discuss the results will be held tomorrow, November 6, 2014, at 8:30 a.m. EST.
RGDO: 0.89 (unch)

Regado Biosciences to Provide Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced that it will hold a conference call and live audio webcast on Thursday, November 6, 2014, at 8:30 a.m. EST to discuss its third quarter 2014 financial results.
RGDO: 0.89 (unch)

Regado Biosciences: Significant Value Remains After Lead Drug Failure
Daniel Ward - at Seeking Alpha - Tue Oct 28, 6:50AM CDT

RGDO: 0.89 (unch)

5 Stocks Ready to Break Out and Soar Higher
at The Street - Mon Oct 20, 9:24AM CDT
These stocks look ready to break out and trade higher from current levels.
VJET: 7.29 (-0.15), RWLK: 21.66 (+0.11), PLX: 1.85 (-0.01), NDLS: 25.88 (+0.20), RGDO: 0.89 (unch)

Regado Biosciences' president gets additional title
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 4:39PM CDT

RGDO: 0.89 (unch)

3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 15, 6:00AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
ATNM: 6.00 (-0.22), RCPI: 0.17 (+0.01), RGDO: 0.89 (unch)

Regado Biosciences names Michael A. Metzger as CEO
M2 - Mon Oct 13, 3:05AM CDT
Biopharmaceutical company Regado Biosciences (NasdaqCM:RGDO) disclosed on Friday the addition of Michael A. Metzger to the additional post of chief executive officer plus as a member of its board of directors.
RGDO: 0.89 (unch)

Regado Biosciences Appoints Michael A. Metzger CEO
PR Newswire - Fri Oct 10, 6:30AM CDT
Regado Biosciences, Inc. (NASDAQ: RGDO), today announced the appointment of Michael A. Metzger, president of Regado, to the additional post of chief executive officer and as a member of the Board of Directors effective immediately. Mr. Metzger previously served as president and chief operating officer of Regado. He replaces David J. Mazzo, Ph.D., who has resigned from the company.
RGDO: 0.89 (unch)

CorMedix Files IND Application for Neutrolin in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 4:10PM CDT
CorMedix Inc. (CRMD) announced that it has filed an Investigational New Drug (IND) application to the FDA for Neutrolin.
CRMD: 1.55 (+0.06), CBM: 21.62 (+0.37), GILD: 91.29 (+1.84), RGDO: 0.89 (unch)

Regado Trims Workforce, Revamps Strategy on Trial Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 30, 3:30PM CDT
Regado (RGDO) has reduced its work force by almost 60%.
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), GILD: 91.29 (+1.84), RGDO: 0.89 (unch)

3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.91 (+0.36), BOTA: 2.26 (unch), RGDO: 0.89 (unch)

Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma
PR Newswire - Fri Sep 26, 7:45AM CDT
The US markets on Thursday, September 25, 2014, declined with the Dow Jones Industrial Average finishing at 16,945.80, down 1.54% and the NASDAQ Composite closing at 4,466.75, down 1.94%. The S&P 500 ended the session 1.62% lower at 1,965.99. During the trading session, all the ten sectors finished on a negative note. The S&P 500 Health Care Sector Index closed the day at 743.47, down 1.58%, whereas the index has advanced 4.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), Regado Biosciences Inc. (NASDAQ: RGDO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Pharmacyclics Inc. (NASDAQ: PCYC), and Raptor Pharmaceutical Corporation (NASDAQ: RPTP). Free research on these five companies can be accessed at:
ACAD: 30.95 (+0.78), PCYC: 121.84 (+1.15), RPTP: 9.34 (+0.56), INCY: 71.57 (+1.99), RGDO: 0.89 (unch)

Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 10.99 (-0.04), STV: 3.07 (-0.05), CNET: 1.28 (-0.11), IG: 9.11 (-0.01), RGDO: 0.89 (unch)

Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
GILD: 91.29 (+1.84), SGEN: 31.10 (-0.14), AMGN: 160.67 (+3.15), RGDO: 0.89 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 21

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 44

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking AI Potential: VERSES Genius™ Surpasses Competitors

Updated Category News Views 353

VERSES Genius™ Agent Sets New Benchmark in AI Performance VERSES AI Inc., a pioneer in cognitive computing, is redefining intelligent systems with its innovative Genius™ toolkit. Recent evaluations against industry-leading benchmarks highlight its significant advancements in artificial intelligence. The preliminary results regarding the "Atari 100K Challenge" showcase...

Continue Reading
MKS Instruments Achieves Loan Repricing and Adds Prepayment

Updated Category News Views 356

MKS Instruments Achieves Loan Repricing and Adds Prepayment MKS Instruments, Inc. (NASDAQ: MKSI), a prominent global leader in enabling technologies, has made a significant leap in optimizing its financial structure. Recently, the company announced it has completed the repricing of its considerable secured tranche B term loans, which amount to a staggering $2.5 billion...

Continue Reading
Incredible Growth of Cheniere Energy: A 15-Year Journey

Updated Category News Views 238

The Remarkable Performance of Cheniere Energy Cheniere Energy, known by its trading symbol LNG, has consistently outperformed the market over the past 15 years. Investors in LNG have witnessed an incredible annualized return of 35.23%, exceeding the market by 22.77%. Currently, Cheniere Energy boasts a market capitalization of $53.26 billion, marking its growth trajectory...

Continue Reading
Adhara and ioBuilders Form New Powerhouse in Blockchain Solutions

Updated Category News Views 420

Adhara and ioBuilders Unite for Blockchain Innovation Adhara and ioBuilders have merged their expertise to create a leading provider of blockchain software products tailored specifically for financial institutions. This strategic alliance has resulted in a profitable company with a robust workforce of over 120 employees, distributed across various regions including the...

Continue Reading
Legal Action Against Lineage, Inc. Following Significant Stock Drop

Updated Category News Views 227

Overview of the Situation Surrounding Lineage, Inc. In recent times, Lineage, Inc. has found itself at the heart of a significant legal controversy following a dramatic 17% drop in its stock price. Leading with this news is the announcement of a class action lawsuit against the company and some of its top executives. Legal firm Bleichmar Fonti & Auld LLP is rallying...

Continue Reading